Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: Progress report on the MRC AML 10 trial

Research output: Contribution to journalArticlepeer-review


  • R. F. Stevens
  • I. M. Hann
  • O. B. Eden
  • C. C. Bailey
  • P. R.H. Barbor
  • A. Barrett
  • C. Barton
  • V. Broadbent
  • J. M. Chessells
  • P. Derbyshire
  • S. I. Dempsey
  • J. Durrant
  • B. Gibson
  • F. G.H. Hill
  • J. Kernahan
  • J. S. Lilleyman
  • J. Mann
  • J. Martin
  • S. T. Mellor
  • P. Morris Jones
  • A. Oakhill
  • J. Peto
  • M. Redford
  • J. K.H. Rees
  • S. M. Richards
  • G. P. Summerfield
  • E. Thompson


The Medical Research Council's AML 10 Children Trial commenced in 1988. It is a multicentre collaberative study based on 4 courses of intensive chemotherapy with additional allogeneic bone marrow transplantation for children with a matched sibling donor. The remaining children are randomised either to an autologous transplant using unpurged marrow or stopping therapy. To date 156 eligible patients have been entered with a CR rate of 91%. 56% of children are still alive 2 years after trial entry and 57% are in CR 3 years after achieving CR. The treatment regimen is intensive but mortality and morbidity are acceptable. The study will need to accrue patients for a further 2 to 3 years in the hope of defining the role of allogeneic and autologous marrow transplantation.


Original languageEnglish
Pages (from-to)55-58
Number of pages4
Issue numberSUPPL. 2
Publication statusPublished - Jun 1992

ASJC Scopus subject areas